Tango Therapeutics Reports Q2 2026 Results

What Happened
Tango Therapeutics, Inc. (TNGX) filed a Form 8-K on August 11, 2026 to furnish a press release reporting its results of operations and financial condition for the quarter ended June 30, 2026. The press release is included as Exhibit 99.1 to the Current Report on Form 8-K. The report was signed by Matthew Gall, Chief Financial Officer, on August 11, 2026.

Key Details

• Press release announcing quarterly results was issued and furnished on August 11, 2026 (Exhibit 99.1).
• Results cover the quarter ended June 30, 2026 (Q2 2026).
• The Form 8-K includes an interactive XBRL cover page data file (Exhibit 104).
• The filing is executed by CFO Matthew Gall.

Why It Matters
This filing makes Tango’s Q2 2026 earnings and financial condition publicly available to investors via the furnished press release and accompanying XBRL data. Retail investors should review the press release and XBRL exhibits for specific figures on revenue, expenses, cash position, and other quarterly metrics to assess the company’s recent performance and trends.